A common β1-adrencrgic receptor polymorphism (Arg389Gly) affects blood pressure response to β-blockade

Clinical Pharmacology and Therapeutics

Volumn 73, Issue 4, 2003, Pages 366-371

  Sofowora, G G ^a   Dishy, V ^a   Muszkat, M ^a   Xie, H G ^a   Kim, R B ^a   Harris, P A ^a   Prasad, H C ^a   Byrne, D W ^a   Nair, U B ^a   Wood, Alastair J J ^a   Stein, C M ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARGININE; ATENOLOL; BETA 1 ADRENERGIC RECEPTOR; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; GLYCINE; BETA ADRENERGIC RECEPTOR;

ADULT; ALLELE; ARTICLE; BETA ADRENERGIC RECEPTOR BLOCKING; CLINICAL ARTICLE; CONTROLLED STUDY; DNA POLYMORPHISM; EXERCISE; FEMALE; GENOTYPE; HEMODYNAMICS; HOMOZYGOSITY; HUMAN; MALE; MEAN ARTERIAL PRESSURE; PHARMACOGENETICS; PRIORITY JOURNAL; SYSTOLIC BLOOD PRESSURE; DRUG EFFECT; GENETIC POLYMORPHISM; GENETICS;

ADRENERGIC BETA-ANTAGONISTS; ADULT; ALLELES; ATENOLOL; FEMALE; GENOTYPE; HEMODYNAMIC PROCESSES; HUMANS; MALE; PHARMACOGENETICS; POLYMORPHISM, GENETIC; RECEPTORS, ADRENERGIC, BETA;

EID: 0037385575     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-9236(02)17734-4     Document Type: Article

References (24)

1. Maqbool A, Hall AS, Ball SG, Balmforth AJ. Common polymorphisms of beta1-adrenoceptor: identification and rapid screening assay. Lancet 1999;353:897.
2. Mason DA, Moore JD, Green SA, Liggett SB. A gain-of-function polymorphism in a G-protein coupling domain of the human beta1-adrenergic receptor. J Biol Chem 1999;274:12670-4.
3. Humma LM, Puckett BJ, Richardson HE, Terra SG, Andrisin TE, Lejeune BL, et al. Effects of beta1-adrenoceptor genetic polymorphisms on resting hemodynamics in patients undergoing diagnostic testing for ischemia. Am J Cardiol 2001;88:1034-7.
4. Bengtsson K, Melander O, Orho-Melander M, Lindblad U, Ranstam J, Rastam L, et al. Polymorphism in the beta(1)-adrenergic receptor gene and hypertension. Circulation 2001;104:187-90.
5. Xie HG, Dishy V, Sofowora G, Kim RB, Landau R, Smiley RM, et al. Arg389Gly beta 1-adrenoceptor polymorphism varies in frequency among different ethnic groups but does not alter response in vivo. Pharmacogenetics 2001;11:191-7.
6. Buscher R, Belger H, Eilmes KJ, Tellkamp R, Radke J, Dhein S, et al. In-vivo studies do not support a major functional role for the Gly389Arg beta 1-adrenoceptor polymorphism in humans. Pharmacogenetics 2001;11:199-205.
7. Osmond DH, McFadzean PA, Scaiff KD. Renin activity by radioimmunoassay: the plasma incubation step. Clin Biochem 1974;7:52-63.
8. Eisenhofer G, Goldstein DS, Stull R, Keiser HR, Sunderland T, Murphy DL, et al. Simultaneous liquid-chromatographic determination of 3,4-dihydroxyphenyl-glycol, catecholamines, and 3,4-dihydroxyphenylalanine in plasma, and their responses to inhibition of mono-amine oxidase. Clin Chem 1986;32:2030-3.
9. Mason WD, Winer N, Kochak G, Cohen I, Bell R. Kinetics and absolute bioavailability of atenolol. Clin Pharmacol Ther 1979;25:408-15.
10. Brown HC, Carruthers SG, Johnston GD, Kelly JG, McAinsh J, McDevitt DG, et al. Clinical pharmacologic observations on atenolol, a beta-adrenoceptor blocker. Clin Pharmacol Ther 1976;20:524-34.
11. Kofahl B, Henke D, Mutschler E. Direct enantiospecific HPLC bioanalysis of (R,S)-atenolol on a chiral stationary phase. Chirality 1993;5:479-82.
12. Frielle T, Collins S, Daniel KW, Caron MG, Lefkowitz RJ, Kobilka BK. Cloning of the cDNA for the human beta 1-adrenergic receptor. Proc Natl Acad Sci U S A 1987;84:7920-4.
13. Gottlieb SS, McCarter RJ, Vogel RA. Effect of beta-blockade on mortality among high-risk and low-risk patients after myocardial infarction. N Engl J Med 1998; 339:489-97.
14. Materson BJ, Reda DJ, Cushman WC, Massie BM, Freis ED, Kochar MS, et al. Single-drug therapy for hypertension in men. A comparison of six antihypertensive agents with placebo. The Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents. N Engl J Med 1993;328:914-21.
15. A trial of the beta-blocker bucindolol in patients with advanced chronic heart failure. N Engl J Med 2001;344: 1659-67.
16. McCoy RA, Clifton GD, Clementi WA, Smith MD, Garvey TQ, Wermeling DP, et al. Pharmacodynamics of racemic and S(-)-atenolol in humans. J Clin Pharmacol 1994;34:816-22.
17. Materson BJ, Reda DJ, Cushman WC. Department of Veterans Affairs single-drug therapy of hypertension study. Revised figures and new data. Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents. Am J Hypertens 1995;8:189-92.
18. Zhou HH, Koshakji RP, Silberstein DJ, Wilkinson GR, Wood AJ. Altered sensitivity to and clearance of propranolol in men of Chinese descent as compared with American whites. N Engl J Med 1989;320:565-70.
19. Kralberg BE, Tolagen K. Different antihypertensive effect of beta-blocking drugs in low and normal-high renin hypertension. Am J Med 1976;60:891-6.
20. Walle T, Byington RP, Furberg CD, McIntyre KM, Vokonas PS. Biologic determinants of propranolol disposition: results from 1308 patients in the Beta-Blocker Heart Attack Trial. Clin Pharmacol Ther 1985;38:509-18.
21. Czendlik CH, Sioufi A, Preiswerk G, Howald H. Pharmacokinetic and pharmacodynamic interaction of single doses of valsartan and atenolol. Eur J Clin Pharmacol 1997;52:451-9.
22. Xie HG, Kim RB, Wood AJ, Stein CM. Molecular basis of ethnic differences in drug disposition and response. Annu Rev Pharmacol Toxicol 2001;41:815-50.
23. O'Shaughnessy KM, Fu B, Dickerson C, Thurston D, Brown MJ. The gain-of-function G389R variant of the beta1-adrenoceptor does not influence blood pressure or heart rate response to beta-blockade in hypertensive subjects. Clin Sci (Lond) 2000;99:233-8.
24. Puckett BJ, Pauly DF, Zineh I, Johnson JA. Beta-adrenergic receptor polymorphisms and antihypertensive response to beta-blocker therapy [abstract]. Clin Pharmacol Ther 2002;71:P2.